Key result
Irbesartan/hydrochlorothiazide combination therapy achieved the target blood pressure goal in 57.3% of Chinese patients with moderate to severe hypertension after 12 weeks of treatment.
Why the study?
Does a fixed combination of irbesartan/hydrochlorothiazide improve blood pressure control in Chinese patients with moderate to severe hypertension?
Does a fixed combination of irbesartan/hydrochlorothiazide improve blood pressure control in Chinese patients with moderate to severe hypertension?
A fixed-dose combination of irbesartan and hydrochlorothiazide effectively lowered blood pressure to target levels in over half of Chinese patients with moderate to severe hypertension, with an acceptable safety profile.
Answers are grounded in this paper and cite their sources.
May support BP control with irbesartan/HCTZ in Chinese patients; leaves open randomized confirmation.
BACKGROUND AND OBJECTIVES: In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension. METHODS: Eligible patients were aged 18-75 years, with a blood pressure of 160-199 mmHg systolic or 100-119 mmHg diastolic during a 1-week wash-out phase off antihypertensive medication. The enrolled patients started antihypertensive treatment with irbesartan/hydrochlorothiazide 150 mg/12.5 mg once daily, with the possible addition of irbesartan 150 mg once daily and up-titration to irbesartan/hydrochlorothiazide 300 mg/25 mg once daily at 4 and 8 weeks of follow-up, respectively. The primary efficacy variable was the goal blood pressure-attaining rate at 12 weeks of follow-up (<140/90 mmHg, or <130/80 mmHg in patients with diabetes mellitus). RESULTS: In the intention-to-treat analysis (n = 501) at 12 weeks of follow-up, the goal blood pressure-attaining rate was 57.3%, and the mean change in blood pressure from baseline was 27.8 mmHg [95% confidence interval (CI) 26.4-29.1 mmHg; p < 0.001] systolic and 13.5 mmHg (95% CI 12.6-14.4 mmHg; p < 0.001) diastolic. Similar findings were observed in the per-protocol analysis (n = 449). The prevalence of microalbuminuria and left ventricular hypertrophy significantly (p ≤ 0.01) decreased from 33.4% (150/449) and 50.4% (215/427) at baseline to 23.4% (105/447) and 41.3% (176/427) at the end of follow-up, respectively. Four patients (2.0%) reported a serious adverse event. CONCLUSION: The fixed irbesartan/hydrochlorothiazide combination may control blood pressure to the target level in about 60% of Chinese patients with moderate to severe hypertension, with an acceptable safety profile.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2013) studied Moderate to severe hypertension (n=501). Irbesartan/hydrochlorothiazide was evaluated on Goal blood pressure-attaining rate at 12 weeks of follow-up (<140/90 mmHg, or <130/80 mmHg in patients with diabetes mellitus). Irbesartan/hydrochlorothiazide combination therapy achieved the target blood pressure goal in 57.3% of Chinese patients with moderate to severe hypertension after 12 weeks of treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: